NCT02936102 2025-11-14A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.NovartisPhase 1 Terminated154 enrolled
NCT04000529 2025-09-30Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesNovartisPhase 1 Terminated122 enrolled
NCT03860272 2025-02-06Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerAgenus Inc.Phase 1 Active not recruiting499 enrolled
NCT03365791 2022-05-27PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic MalignanciesNovartisPhase 2 Completed76 enrolled 14 charts
NCT04607200 2022-01-11AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable AngiosarcomaAgenus Inc.Phase 2 Withdrawn